EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.

Bibliographic Details
Main Authors:	A. Catapano, E. V. Shlyakhto, A. I. Martynov, R. G. Oganov, V. V. Kukharchuk, M. V. Shestakova, A. S. Ametov, S. A. Boicov, M. G. Bubnova, S. V. Villevalde, A. S. Galyavich, Yu. A. Karpov, J. D. Kobalava, O. N. Koziolova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2013-08-01
Series:	Кардиоваскулярная терапия и профилактика
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/217

Similar Items

Ezetimibe potential in cardiology practice
by: A. A. Lyakishev, et al.
Published: (1970-01-01)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
by: Alexander, W, et al.
Published: (2011)

Simultaneous inhibition of cholesterol absorption and synthesis in combined therapy with ezetimibe and simvastatin
by: D. M. Aronov
Published: (2005-08-01)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
by: Agata Górniak, et al.
Published: (2022-04-01)

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia
by: M. Yu. Zubareva, et al.
Published: (2010-12-01)

Serum lipids and smoking status in coronary heart disease patients treated with simvastatin
by: L. R. Gazdanova, et al.
Published: (2010-04-01)

Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering.
by: Gounari, P, et al.
Published: (2010)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Ezetimibe and diabetes mellitus:a new strategy for lowering cholesterol
by: V.A. Serhiyenko, et al.
Published: (2022-09-01)

Combined lipid-lowering therapy: choosing strategy and tactics
by: N. A. Koziolova
Published: (2010-08-01)

Ezetimibe-Loaded Nanostructured Lipid Carrier Based Formulation Ameliorates Hyperlipidaemia in an Experimental Model of High Fat Diet
by: Yogeeta O. Agrawal, et al.
Published: (2021-03-01)

GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS
by: M. A. Vorobyeva, et al.
Published: (2017-09-01)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

Clinical effects of statins: focusing on simvastatin
by: D. M. Aronov, et al.
Published: (2009-04-01)

Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr−/−Mice
by: Shamuha Bahetibieke, et al.
Published: (2022-06-01)

Effects of Simvastatin on Lipid Metabolism in Wild-Type Mice and Mice with Muscle PGC-1α Overexpression
by: Miljenko V. Panajatovic, et al.
Published: (2021-05-01)

The Effect of Ezetimibe on Lipid Profile and Renal Function and its Side Effects in Renal Transplant Recipients
by: Shahrzad Shahidi, et al.
Published: (2011-01-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
by: N. V. Perova, et al.
Published: (2016-01-01)

Implemented models and perspectives of managing lipid metabolism disorders. Concept of rare lipid disease centers
by: A. S. Alieva, et al.
Published: (2021-07-01)

Formulation and Evaluation of Ezetimibe Nanoparticles
by: Yasser A.Ali, et al.
Published: (2017-03-01)

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
by: Joel Rodríguez-Saldaña, et al.
Published: (2022-01-01)

Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy
by: I. A. Alekseeva, et al.
Published: (2020-10-01)

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
by: V. V. Yakusevich, et al.
Published: (2015-12-01)

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
by: V. V. Yakusevich, et al.
Published: (2015-12-01)

Simvastatin therapy in climacteric women with atherogenic dyslipoproteinemias
by: N. V. Izmozherova, et al.
Published: (2008-04-01)

Simvastatin therapy in patients with hepatic disease
by: O. M. Drapkina, et al.
Published: (2007-10-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

From lipid analysis to lipidomics
by: V. A. Akmurzina, et al.
Published: (2012-12-01)

Effects of combined therapy with atorvastatin and polyunsaturated omega-3 fatty acids on lipid profile, lipoprotein-associated phospholipase A2 and thromboxane
by: G. F. Piksina, et al.
Published: (2010-10-01)

Effect of Simvastatin on the spectrum of blood plasma fat acids change in the patients with ischemia heart disease
by: V. V. Novitsky, et al.
Published: (2008-09-01)

THE ASSESSMENT OF EFFECTS OF COMBINED THERAPY WITH MILDRONATE ON LIPID PROFILE, INFLAMMATORY FACTORS AND ENDOTHELIUM FUNCTION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: I. V. Sergienko, et al.
Published: (2015-12-01)

THE ASSESSMENT OF EFFECTS OF COMBINED THERAPY WITH MILDRONATE ON LIPID PROFILE, INFLAMMATORY FACTORS AND ENDOTHELIUM FUNCTION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: I. V. Sergienko, et al.
Published: (2015-12-01)

Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis
by: Ruping Cai, et al.
Published: (2023-01-01)

NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

BLOOD LIPID AND NON-LIPID BIOMARKERS IN NOVOSIBIRSK MEN WITH CORONARY ATHEROSCLEROSIS
by: Yu. I. Ragino, et al.
Published: (2009-04-01)

EFFECTIVENESS AND SAFETY OF LISINOPRIL AND SIMVASTATIN COMBINATION – ELASTICA STUDY RESULTS
by: F. T. Ageev, et al.
Published: (2009-02-01)

ANTIISCHEMIC AND ANTIARRHYTHMIC EFFECTS OF SIMVASTATIN IN PATIENTS WITH DIASTOLIC HEART FAILURE
by: T. V. Pinchuk, et al.
Published: (2013-12-01)